Proxigel

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Proxigel

Quick Facts: Proxigel

Property Description
Active ingredient Piroxicam
Form Gel (Semi-solid preparation)
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Localized relief of pain and inflammation
Origin Synthetic (Oxicam derivative)

The Pharmaceutical Identity and Classification

Proxigel is formally classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), containing the active ingredient Piroxicam (International Nonproprietary Name). Piroxicam itself is a synthetic chemical compound that belongs to the oxicam family, a specific subclass of NSAIDs. Piroxicam possesses anti-inflammatory properties and the capacity to reduce painful symptoms.


Composition and Targeted Delivery

The Proxigel preparation is a single-ingredient product where the active Piroxicam is contained within an aqueous or hydroalcoholic gel base. This formulation determines the route of administration as topical; it is applied directly to the skin. This specialized delivery system is utilized to ensure that the anti-inflammatory component is delivered primarily to the underlying tissues, such as muscles or joints, where the inflammation is located. The use of Piroxicam in a topical preparation allows the drug to achieve high concentrations in the affected joint tissues while minimizing systemic exposure compared to the widely distributed oral form. This unique targeted approach is a key feature of the gel formulation.


General Therapeutic Purpose

The overall purpose of Proxigel is to provide localized relief from pain and inflammation associated with common musculoskeletal complaints. In its role as an NSAID, Piroxicam works by temporarily interfering with the body's production of prostaglandins, the chemical mediators that cause swelling, redness, and pain signals. This targeted action allows the medication to manage the discomfort associated with the inflammatory response at the site of application.

What side effects are possible with Proxigel?

Possible Side Effects and Safety Information

The following safety information for Proxigel (Chlorhexidine Gluconate oral gel) is based on official government regulatory documents and post-marketing surveillance reports.


Adverse Reactions

Adverse reactions associated with this product are formally classified by frequency and by the affected body system (System-Organ Class).

Frequency-Classified Adverse Reactions

Classification Examples of Documented Side Effects
Common Increased staining of teeth and other oral surfaces, increase in the formation of dental calculus (tartar), temporary alteration in taste perception (dysgeusia).
Rare Serious allergic reactions (including anaphylaxis), swelling of the salivary glands (parotid gland swelling), and permanent taste alteration.

System-Organ Classes Involved

The most commonly affected regulatory categories are Gastrointestinal Disorders (oral symptoms and taste alteration) and General Disorders and Administration Site Conditions. The Immune System Disorders class includes the rare but serious hypersensitivity reactions.


Serious Adverse Reactions and Safety Restrictions

Serious Adverse Reactions

Life-threatening or fatal anaphylaxis (a severe, whole-body allergic reaction) has been documented in association with the active ingredient. These reactions can occur rapidly, often within minutes of product use.

Safety Restrictions and Limitations

This medication is contraindicated (should not be used) in any individual who has a known hypersensitivity or allergy to the active substance or any other component in the formulation. The safety and effectiveness of this oral preparation have not been formally established for use in pediatric patients (those under 18 years of age) according to one regulatory source.

Long-term use is explicitly associated with an increased incidence of tooth staining and calculus formation.

Overdose and Emergency Response

Overdose and When to Seek Help

The risk of systemic overdose with Proxigel (topical Piroxicam) is officially considered unlikely due to its formulation as a gel and the low levels of active ingredient absorbed through the skin. Overdose information primarily addresses situations of accidental ingestion of the product, aligning with the regulatory profile for systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs).


Documented Manifestations and Actions

Category Officially Documented Manifestation or Action
Documented Symptoms Nausea, vomiting, stomach pain, and drowsiness
Local Risk Local irritation (if over-applied topically)
Antidote No specific antidote is documented

Required Emergency Actions

In case of accidental ingestion, individuals must immediately call a POISON CENTER/doctor for guidance. It is critical that vomiting must not be induced. Following such an event, healthcare providers are required to provide appropriate symptomatic and supportive treatment and monitor vital signs, often involving a period of hospital observation. If an excess amount of the gel is applied topically, the instruction is to rinse the area well with water.

Therapeutic Uses of Proxigel

What Proxigel Treats: Main Uses and Benefits

Proxigel (topical Piroxicam) may assist with managing the pain and inflammation associated with common musculoskeletal issues. The active ingredient is used across therapeutic domains where temporary functional strain or discomfort is driven by inflammatory or irritative states, offering supportive relief that may help patients cope more steadily with symptom fluctuations.


Therapeutic Domains and Symptom Relief

The preparation is commonly used across conditions presenting with acute or recurrent episodes, including muscle strains, ligament sprains, minor trauma, localized symptoms of osteoarthritis, and specific overuse syndromes like tendinitis and bursitis. It helps address symptom clusters that may become intense or disruptive, such as pronounced pain, swelling, and tenderness that interfere with daily functioning.

“It is relevant for easing symptoms related to the primary goal of symptomatic support when symptoms interfere with routine activities and lead to temporary functional strain.”

By managing these symptoms, Proxigel supports patients during episodes of heightened discomfort and may assist with maintaining functional stability in the affected area.


Quick Fact: Relief for Localized Musculoskeletal Pain

Symptom Focus Context Benefit
Pain and Swelling Acute soft tissue injuries, strains, sprains Contributes to easing the overall symptom load
Stiffness and Tenderness Localized arthritis, chronic flare-ups Supports general well-being during symptomatic phases
Inflammatory Discomfort Tendinitis, bursitis, overuse syndromes Helps patients cope more steadily with symptom fluctuations

Regulatory References

  1. HPRA (Ireland) Patient Information Leaflet

Eligibility and Restrictions for Use

Who Can and Cannot Use Proxigel?

Proxigel (topical Piroxicam) eligibility is defined by regulatory guidelines, primarily restricting use based on age, allergy history, and reproductive status. The medicine is approved for use in adults and adolescents 12 years of age and older.

Absolute Contraindications

Use is strictly prohibited for patients with:

  • Hypersensitivity or Allergy: Known allergy to Piroxicam, any excipient, or cross-sensitivity to Aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).
  • NSAID-Induced Reactions: A history of NSAID or Aspirin inducing conditions like asthma, urticaria, or nasal polyps.
  • Late-Stage Pregnancy: Women from the start of the 6th month of gestation.
  • Specific Reaction History: A history of Piroxicam-related Fixed Drug Eruption (FDE).

Conditional Use and Non-Eligibility

Population Group Regulatory Status
Children Under 12 Not Suitable For Use. Safety and efficacy are not established for children in this age group.
Pregnant Women Contraindicated in the third trimester; Not Recommended in the first two trimesters.
Nursing Mothers Not Recommended as clinical safety for the infant has not been established.
Renal Impairment Requires Caution and Monitoring of kidney function due to potential deterioration.

The product is also contraindicated for application to any open skin lesions, damaged skin, or near the eyes and mucous membranes.

What should I know about interactions with other medicines?

The interaction profile for Proxigel's active ingredient, Piroxicam, is based on the documented systemic effects of the NSAID class, which are considered due to the potential for absorption from topical application.

Documented Interaction Restrictions

Classification Interacting Substance or Context
Contraindicated Co-administration with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective agents and aspirin at analgesic doses
Contraindicated Use in the peri-operative setting of Coronary Artery Bypass Graft (CABG) surgery
High-Risk Concomitant use with oral anticoagulants (e.g., warfarin) and drugs that interfere with hemostasis (e.g., SSRIs/SNRIs) due to the substantial increase in bleeding risk.

Pharmacodynamic and Exposure Interactions

The regulatory profile documents that Piroxicam may diminish the therapeutic effect of several drug classes, including ACE Inhibitors, Angiotensin Receptor Blockers (ARBs), and diuretics (e.g., Furosemide). Concomitant use with Digoxin can result in increased serum concentration and prolonged half-life of Digoxin. Additionally, alcohol consumption is explicitly stated to substantially increase the risk of serious gastrointestinal complications. Individuals who are CYP2C9 poor metabolizers are noted in official labeling to be at risk for abnormally high systemic drug levels due to reduced clearance. The combination of Piroxicam with ACE Inhibitors or ARBs is specifically noted to result in the deterioration of renal function in susceptible populations, such as the elderly or those with renal impairment.

Mechanism of Action

How Proxigel Works

Proxigel is an active agent precursor that initiates its effect following chemical decomposition upon contact with aqueous environments, such as tissue surfaces or fluids. The active component, carbamide peroxide, dissociates to release urea and hydrogen peroxide (H2O2). The resulting physiological effects are mediated by these two liberated molecules.

Modulation of Cellular Environment via Oxidation

Hydrogen peroxide acts as a strong oxidizing agent, generating the perhydroxyl free radical (HO2^-). This mechanism engages the oxidation of biological molecules, disrupting the chemical bonds of cellular and non-cellular components, thereby contributing to modulating the magnitude of physiological responses at the localized site. This oxidative sequence alters molecular signaling, which helps define the pathway response.

Hydration and Physical Disintegration

The released urea and hydrogen peroxide act to hydrate and induce a mild keratolytic effect. This facilitates the mechanical disintegration and softening of accumulated material and tissue slough. Concurrently, the decomposition of hydrogen peroxide rapidly releases oxygen, creating an environment unfavorable to anaerobic microorganisms. This action alters the local microbial equilibrium, modifying effects resulting from increased mediator activity within targeted pathways.

Dosage and Administration Information

Proxigel (Piroxicam 0.5% Gel) is intended for the topical route of administration, meaning the preparation is applied externally directly to the skin. The medicine is provided as a 0.5% gel, with each gram containing 5 milligrams of the active ingredient.

Administration Dosing and Frequency

The standard adult application quantity is 1 gram of gel per application. This amount corresponds to an approximate strip length of 3 cm. This quantity is applied to the affected area and must be gently massaged into the skin until no residual material remains visible on the surface. This dose is applied three to four times daily.

Contextual Instructions and Restrictions

To ensure proper use, several specific administration conditions apply. The application site must not be covered with occlusive (airtight) bandages or dressings, as this could alter the intended use conditions. Contact with the eyes and mucous membranes must also be strictly avoided. Hands should be washed thoroughly after application, unless the hands are the area being treated.

Population and Duration Rules

Use of the gel is generally recognized for short-term administration. The necessity of continued therapy is recommended to be reviewed at regular intervals, particularly if use extends past four weeks. Furthermore, dosage recommendations and indications for the use of Piroxicam 0.5% gel have not been established for children, making it an administration pattern reserved for the adult population.

Recent Clinical Evidence

Evidence for Use in Localized Osteoarthritis

This section will summarize the structure of the clinical research for localized osteoarthritis, detailing the types of studies conducted—primarily randomized controlled trials (RCTs) and systematic meta-analyses—and the specific outcomes that were measured, such as pain and functional scores.

Research was studied for conditions marked by functional limitations and the resulting outcomes related to physical discomfort. Studies primarily examined adults with symptomatic, localized osteoarthritis, often focusing on joints like the knee. Researchers monitored outcomes reflecting daily functioning or activity level using standardized measures over defined time intervals. These trials were largely short-term, typically lasting around four weeks.

Findings describe patterns observed in the studies regarding patient-reported outcomes describing perceived discomfort when Proxigel was evaluated in these conditions. The research describes patterns in changes measured during the study period, including daily activity level. Evidence describes symptom patterns observed over defined time intervals.

Evidence for Use in Acute Soft Tissue Injuries

This part will detail the research landscape for acute conditions, including sprains, strains, and tendinitis. It will focus on the design of the short-term RCTs and the specific timeframes and measures used by researchers to assess changes in acute symptoms.

Research was studied for conditions involving periods of heightened symptoms, such as acute soft tissue injuries or tendinitis. Studies explored the use of Proxigel in research contexts involving fluctuating or unstable symptoms. Trials monitored outcomes describing episodic or acute changes in pain, as well as the time required for symptoms to evolve in the observed populations.

Studies report how symptoms evolved in the observed populations over very short, defined time intervals, typically ranging from three to seven days. Findings describe patterns observed in the studies related to outcomes capturing phases of heightened symptom activity. Comparative evidence data show patterns related to symptom evolution, though findings were mixed when compared across different topical agents in some research scenarios.

Long-Term Studies and Durability of Effect

The evidence base primarily consists of research conducted during periods of increased symptom activity and focuses on short-term symptom changes. The body of work is primarily applicable to research assessing short-term or episodic symptom patterns. There is limited information for long-term outcomes that would provide a clear understanding of the durability of the observed changes after the short study periods conclude. Existing studies are not designed to determine how symptoms may evolve over many months or years.

Evidence in Special Populations and Subgroups

This section outlines what research has been conducted in populations beyond the general adult cohort. While Proxigel was observed in older adults in some trials, data for certain groups remain insufficient, including for pregnant populations or those with specific comorbid conditions that can affect outcomes. Furthermore, the existing research has not sufficiently examined outcomes for deeper anatomical locations in conditions marked by functional limitations; studies available primarily evaluated outcomes in easily accessible joints (like knees).

Research Gaps and What Remains Uncertain

The research highlights what is known — and what is still uncertain about the application of Proxigel. For conditions characterized by fluctuating or episodic manifestations, the available evidence is limited by the fact that follow-up durations were limited. The findings reflect the specific conditions under which they were conducted, meaning results apply only to the populations studied. Sample sizes were modest in some instances, and evidence quality varies across studies, leading to mixed findings across the broader evidence landscape. Overall, the research provides context but not individual predictions, and long-term effects are not fully established for either primary condition studied.

Key Studies & References

  1. Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis

Frequently Asked Questions (FAQ)

Common questions about Proxigel (FAQ)


Q: What is Proxigel used for besides the main condition?

According to official product documents, Proxigel is indicated for use in specific musculoskeletal conditions. These uses primarily involve the relief of signs and symptoms associated with localized osteoarthritis and acute soft tissue injuries. Regulatory information focuses on these defined areas of use.


Q: Is Proxigel the same type of medicine as [similar drug name]?

The active ingredient in Proxigel is Piroxicam, which places it in the class of Nonsteroidal Anti-inflammatory Drugs, or NSAIDs. Piroxicam is further specified as belonging to the oxicam family of these medicines. This classification defines its chemical and pharmacological identity.


Q: How quickly does Proxigel start to work?

Official research reports do not specify an exact time for the onset of effect. Studies evaluating Proxigel's use, particularly for acute symptoms, commonly monitored patient-reported outcomes over short, defined time intervals, such as those ranging from three to seven days.


Q: What is the longest period of time you can use Proxigel?

Proxigel is generally intended for short-term administration. Official prescribing documents recommend that the need for continued therapy be reviewed at regular intervals, particularly if the treatment extends beyond four weeks.


Q: Is it normal to feel a mild burning sensation when first applying Proxigel?

Official guidance does not specifically list 'burning' but does acknowledge local effects. The application instructions note that if the gel is applied to injured or broken skin, it may cause a 'sore sensation.'


Q: Can Proxigel cause drowsiness or affect my ability to drive?

The active ingredient in this medication is associated with reported effects on the nervous system. These documented side effects include reports of dizziness and somnolence (drowsiness).


Q: Do any foods or drinks need to be avoided while using Proxigel?

Official regulatory information specifically notes the warning regarding alcohol consumption. It is stated that alcohol substantially increases the risk of serious gastrointestinal complications when using medication containing the active ingredient, Piroxicam.


Q: Are there any special warnings for older adults using Proxigel?

The active ingredient's official labeling contains specific warnings concerning older adults. These individuals are noted as a susceptible population when using the medication alongside certain drug classes, such as ACE Inhibitors or ARBs, due to the potential for a decline in kidney function.


Q: What is the difference between Proxigel and a steroid cream?

Proxigel and steroid creams belong to different pharmacological classes of medicine. Proxigel is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), while steroid creams contain corticosteroids.


Q: Has Proxigel been tested on pregnant women?

Regulatory safety summaries indicate that human data on NSAID use during the first two trimesters of pregnancy are inconclusive regarding potential risks to the fetus. Official information is often supported by animal studies, which have revealed evidence of effects such as fetotoxicity.


Q: Is Proxigel a common cause of skin rash?

Regulatory safety documents note that the active ingredient is associated with reported skin-related adverse reactions. Rash is listed among the commonly reported side effects linked to the overall use of the medication.


Q: Can I use Proxigel if I have kidney problems?

Individuals with kidney problems (renal impairment) require caution and monitoring during use. For patients with advanced kidney disease, regulatory information advises against use of the active ingredient unless clinical judgment determines the benefits outweigh the risk of worsening kidney function.


Q: What happens if I forget to use a dose of Proxigel?

Official dosing guidance provides instruction for this situation. If a dose is missed, regulatory guidance recommends applying it as soon as it is remembered, however, regulatory guidance prohibits the use of a double or excessive dose at one time.


Q: Why is Proxigel called a 'gel' if it's used internally (or applied topically)?

Proxigel is classified as a gel because of its physical state—a semi-solid preparation. This preparation contains the active ingredient within an aqueous or hydroalcoholic base, which is designed for the product to be administered topically, or applied directly to the skin.


Q: What are the most commonly reported side effects of Proxigel?

According to official adverse event reports, the active ingredient is associated with commonly reported systemic effects. These may include symptoms such as rash, headache, dizziness, and minor gastrointestinal issues, such as nausea or flatulence.


Q: Can Proxigel affect blood sugar levels?

Official interaction data documents that using the active ingredient with certain diabetes medications (like Metformin) can lead to a documented complication called lactic acidosis.


Q: Do healthcare professionals recommend a follow-up appointment after starting Proxigel?

Official prescribing information states that the necessity of ongoing use is recommended to be reviewed at regular intervals, particularly if use continues beyond four weeks.


Q: How is Proxigel eliminated from the body?

According to official regulatory documents detailing the drug's path through the body, the active ingredient, Piroxicam, is metabolized. The resulting drug products are eliminated from the body via both urine and feces.


Q: Is it true that Proxigel should not be exposed to direct sunlight?

Regulatory safety information for the active ingredient includes warnings regarding increased skin sensitivity to light, a condition called photosensitivity. Due to this photosensitivity risk, the use of protective measures against sun exposure is noted in official information.


Q: Is Proxigel considered a high-risk medication?

Regulatory documents contain several documented warnings related to potential serious risks, including cardiovascular and gastrointestinal complications. These documented risks necessitate the implementation of official Risk Minimization Measures in certain regulatory regions.


Q: Does Proxigel interact with herbal supplements?

Official interaction data indicates that the active ingredient may interact with certain herbal products. Specifically, interaction data notes that certain herbal products like agrimony and American ginseng have been associated with an increased risk of anticoagulation or bleeding.


Q: What is the half-life of Proxigel in the body?

The active ingredient, Piroxicam, has a long plasma half-life of approximately 50 hours after systemic exposure (like oral administration). The half-life refers to the time it takes for the concentration of the substance to be reduced by half.


Q: Is it true that Proxigel should not be swallowed?

Proxigel is formulated and designated solely for external topical use. Official prescribing information states that contact with the eyes and any mucous membranes, such as those inside the mouth, should be avoided.


Q: Can Proxigel cause changes in mood or behavior?

The active ingredient in this medicine is associated with reported side effects on the central nervous system. In rare instances, regulatory safety documents have noted changes such as anxiety and confusion among the reported adverse events.


Q: Does Proxigel come with a patient information leaflet (PIL)?

Yes, as a regulated medicine, the packaging typically includes a Patient Information Leaflet, or PIL. This document contains detailed safety and usage information that has been approved by the relevant governmental regulatory authority.

How should Proxigel be stored and disposed of?

How to Store and Dispose of Proxigel

The storage and disposal of Proxigel (Piroxicam gel) must strictly adhere to the conditions mandated by official regulatory labeling to ensure product stability and safety.

Condition Type Official Requirement
Temperature Store at room temperature, generally not exceeding 25°C or 30°C.
Protection Keep away from excess heat and moisture, such as in a bathroom.
Packaging Keep the medication in the original container and the cap tightly closed.
Child Safety Store the gel out of the sight and reach of children.

For disposal, the product should not be placed in the toilet or sink. Expired or unused gel should be discarded via a drug take-back program or by mixing it with an undesirable substance (e.g., used coffee grounds) in a sealed container before placing it in household trash, following official guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Proxigel found in:

A-Z Index: